News Category
In vitro ADME studies are becoming essential for efficient drug development, helping to identify promising candidates early and avoid costly late-stag...
GeoVax announced preclinical findings that its enhanced MVA-X vaccine provides durable single-dose protection against highly pathogenic Clade I mpox, ...
Onco-Innovations is advancing its preclinical cancer candidate ONC010 toward first-in-human testing by integrating manufacturing, formulation, preclin...
VERAXA Biotech has named Raju Willener as its new chief financial officer, bringing over 30 years of capital markets experience as the company advance...
Apimeds Pharmaceuticals US, Inc. has hired IBN to enhance its corporate communications strategy, aiming to increase visibility for its biopharmaceutic...
Regentis Biomaterials is advancing its lead cartilage repair product GelrinC through a U.S. pivotal trial and European commercialization, targeting a ...
Silo Pharma receives a Notice of Allowance from the USPTO for a patent covering its intranasal PTSD treatment SPC-15, strengthening its intellectual p...
Regentis Biomaterials is moving its GelrinC hydrogel implant into a pivotal study stage, offering a potential off-the-shelf solution for knee cartilag...
Telomir Pharmaceuticals (NASDAQ: TELO) announced peer-reviewed preclinical research showing its lead candidate Telomir-Zn improved visual function and...
Scientists are investigating accelerated biological aging as a potential explanation for the increasing incidence of cancer in adults under 55, a tren...
Lantern Pharma's subsidiary Open-Medicine AI will host a webinar on September 23 to present its AI platform, business model, and expansion plans, sign...
Rodman & Renshaw analyst Michael G. King Jr. initiated coverage of Quantum BioPharma with a Buy rating and $8 price target, highlighting the company's...
VolitionRx has joined a €6.3 million French government-funded consortium to develop an early sepsis detection test using its Nu.Q NETs biomarker, targ...
VERAXA Biotech has named Raju Willener as CFO, bringing over 30 years of capital markets experience as the company advances its BiTAC oncology platfor...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, as it seeks U.S. approval through...
Med-X is expanding its Nature-Cide natural pest control brand as it prepares for a Nasdaq debut, aiming to capture growing demand for eco-friendly pes...
Telomir Pharmaceuticals announced new research findings showing its lead drug candidate Telomir-Zn inhibited growth in human and canine osteosarcoma c...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could lead to an additional qualified source of m...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers overcome stability, targetin...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing solutions to help researchers overcome sample processing challenges and a...
A new review reveals that the tumor microenvironment drives natural killer cells into diverse functional subsets, offering a framework for more precis...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin cancer therapy, highlighting th...
Regentis Biomaterials reported a reduced net loss for the first half of 2026 and progress in its pivotal U.S. trial for GelrinC, a potential off-the-s...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug that aims to protect and ...
TransCode Therapeutics has named John Tattory as interim CFO following Tom Fitzgerald's retirement, a change that comes as the clinical-stage company ...
VERAXA Biotech has named Dr. Christoph Erkel as chief scientific officer to lead the advancement of its BiTAC® technology and oncology pipeline, a mov...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor for multiple sclerosis, is moving toward a Phase 2 trial following FDA clea...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and po...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis treatment designed to shield a...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, drawing attention to the compan...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting cancer drug ONC010, which uses synthetic lethality and nanoparticle delivery to pote...
Quantum BioPharma's Lucid-MS has received FDA clearance for a Phase 2 trial in multiple sclerosis, marking a significant step for a novel treatment ap...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak pressures of 100,000 atmospheres and attracting new equ...
Kairos Pharma's CEO will present at the H.C. Wainwright conference, highlighting its lead candidate ENV-105 designed to overcome cancer drug resistanc...
Nutriband's CEO will attend the Nasdaq LaB Biotech Summit, showcasing its AVERSA technology aimed at preventing opioid abuse, a critical issue in publ...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum highlights progress in its nose-to-brain drug delivery platform, with new stabi...
Quantum BioPharma announced FDA clearance for its Phase 2 trial of Lucid-MS, a first-in-class candidate for multiple sclerosis, which has drawn analys...
Quantum BioPharma Ltd. has received FDA clearance to begin a Phase 2 clinical trial for its multiple sclerosis drug candidate Lucid-MS, a milestone th...
Helus Pharma's CEO participation in a major investment conference underscores the company's progress in developing novel treatments for depression and...
GeoVax applauds the new Gavi-funded global mpox vaccine stockpile as a step toward sustained preparedness, while highlighting its GEO-MVA candidate's ...
Voyageur Pharmaceuticals has achieved the first milestone in its Bayer-funded feasibility study for iodine production, receiving a $1 million payment ...
Greenland Mines announces Q4 biotech spin-off, Nasdaq compliance, and Sarfartoq acquisition, positioning itself as a key rare earths supplier outside ...
VERAXA Biotech (NASDAQ: VRXA) has named veteran financial executive Raju Willener as CFO, effective immediately, to support its capital strategy and a...
Scinai Immunotherapeutics has ended its PC111 license agreement with PinCell to focus resources on its NanoAb platform and expanding CDMO business, ai...
Onco-Innovations Ltd. advances its oncology pipeline with key milestones in manufacturing, IND-enabling activities, partnerships, and funding, positio...
OS Animal Health, a subsidiary of OS Therapies, showcased its innovative HER2-targeting immunotherapy for canine osteosarcoma at the Moody Capital Sol...
